- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Amersham targets Alzheimer's disease
British pharmaceutical and life sciences company Amersham has obtained an exclusive license from the University of Pittsburgh to a class of molecules that target amyloid plaque in the brain, the cause of Alzheimer's disease. Amersham will attempt to
British pharmaceutical and life sciences company Amersham has obtained an exclusive license from the University of Pittsburgh to a class of molecules that target amyloid plaque in the brain, the cause of Alzheimer's disease. Amersham will attempt to develop PET agents for diagnosing and monitoring the progress of the disease. Such agents could accelerate the development of a wide range of therapeutics for Alzheimer's by allowing doctors to definitively measure the effectiveness of a potential therapy, according to the company.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
